Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

61 questions · 73 findings · 9 reviews

No studies found 9 · 12.3%GRADE not reported 8 · 11%Very low 29 · 39.7%Low 17 · 23.3%Moderate 7 · 9.6%High 3 · 4.1%

Osmotic‐release oral system methylphenidate vs placebo

Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy

Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).

1 finding from 1 review

Intervention not reported

Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review

Intervention not reported

Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review

Intervention not reported

Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review

Intervention not reported

Withdrawal of methylphenidate for unknown reasons Measure by: proportion of participants withdrawn from treatment Average study duration (range): 6.13 months (1 day to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review

Intervention not reported

Serious adverse events Measured by: proportion of serious adverse events (total) Average study duration (range): not stated · children and adolescents aged 18 years and under diagnosed with ADHD

It is very uncertain whether the intervention changes serious adverse events Measured by: proportion of serious adverse… (very low certainty).

1 finding from 1 review